Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Surg Oncol ; 113(1): 108-13, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26661586

RESUMO

BACKGROUND AND OBJECTIVES: Currently, standard treatment of soft tissue sarcoma (STS) is wide local excision and adjuvant radiation, but radiation may be unnecessary in superficial STS. The primary objective is to assess local recurrence rates in patients treated with surgical management alone for superficial STS. METHODS: A retrospective cancer registry review of patients treated with surgery alone for superficial STS at the Tom Baker Cancer Center (TBCC) was performed. Patient and tumor characteristics as well as recurrence data were collected. RESULTS: Sixty-one patients met study criteria. Local and overall recurrence rates were 7/61 (11.5%) and 12/61 (19.7%), respectively. The proportion with a T2 tumor was 38.8% versus 33.3% (P = 0.69), with Grade 2 or 3 tumors was 59.2% versus 83.3% (P = 0.14), and with resection margins <1 cm was 28.6% versus 75.0% (P = 0.008) for patients without and with recurrence, respectively. Median time to recurrence was 1.7 (0.4-5.2) years. CONCLUSIONS: Surgical resection alone appears to be a viable option for superficial STS that can save patients from potential side effects of radiation. The association between recurrence and inadequate margins (<1 cm) requires additional treatment be offered to this subset of patients.


Assuntos
Sarcoma/patologia , Sarcoma/cirurgia , Adulto , Idoso , Alberta/epidemiologia , Intervalo Livre de Doença , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Prontuários Médicos , Pessoa de Meia-Idade , Gradação de Tumores , Recidiva Local de Neoplasia/epidemiologia , Seleção de Pacientes , Sistema de Registros , Estudos Retrospectivos , Sarcoma/epidemiologia , Sarcoma/mortalidade , Resultado do Tratamento
2.
Can J Surg ; 56(5): 347-52, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24067520

RESUMO

Obesity is a common disease affecting adults and children. The incidence of obesity in Canada is increasing. Laparoscopic sleeve gastrectomy (LSG) is a relatively new and effective procedure for weight loss. Owing to an increase in the number of bariatric surgical procedures, general surgeons should have an understanding of the complications associated with LSG and an approach for dealing with them. Early postoperative complications following LSG that need to be identified urgently include bleeding, staple line leak and development of an abscess. Delayed complications include strictures, nutritional deficiencies and gastresophageal reflux disease. We discuss the principles involved in the management of each complication.


L'obésité est une maladie fort répandue, tant chez les adultes que chez les enfants, et son incidence est en hausse au Canada. La gastrectomie longitudinale laparoscopique (GLL) est une intervention relativement nouvelle et efficace pour la perte de poids. Compte tenu de l'augmentation du nombre d'interventions chirurgicales bariatriques, les chirurgiens généralistes doivent se familiariser avec les complications associées à la GLL et avec leur prise en charge. Les complications postopératoires immédiates de la GLL qu'il faut savoir reconnaître sans retard sont l'hémorragie, les fuites le long de la ligne d'agrafes et la formation d'abcès. Parmi les complications plus tardives, mentionnons les sténoses, les carences alimentaires et le reflux gastro-œsophagien. Nous présentons les principes qui sous-tendent la prise en charge de chaque complication.


Assuntos
Gastrectomia/efeitos adversos , Gastrectomia/métodos , Laparoscopia/efeitos adversos , Abscesso Abdominal/cirurgia , Adulto , Constrição Patológica , Descompressão Cirúrgica , Humanos , Desnutrição/epidemiologia , Desnutrição/terapia , Obesidade Mórbida/cirurgia , Pneumoperitônio Artificial , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/terapia , Hemorragia Pós-Operatória/epidemiologia , Hemorragia Pós-Operatória/cirurgia , Stents
3.
Obes Surg ; 23(3): 414-23, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23299507

RESUMO

There is a strong relationship between obesity and the development of obstructive sleep apnea (OSA). Respectively, bariatric surgery is often touted as the most effective option for treating obesity and its comorbidities, including OSA. Nevertheless, there remains paucity of data in the literature of the comparison of all the specific types of bariatric surgery themselves. In an effort to answer this question, a systematic review was performed, to determine, of the available bariatric procedures [Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, or biliopancreatic diversion (BPD)], which procedures were the most efficacious in the treatment of OSA. A total of 69 studies with 13,900 patients were included. All the procedures achieved profound effects on OSA, as over 75 % of patients saw at least an improvement in their sleep apnea. BPD was the most successful procedure in improving or resolving OSA, with laparoscopic adjustable gastric banding being the least. In conclusion, bariatric surgery is a definitive treatment for obstructive sleep apnea, regardless of the specific type.


Assuntos
Cirurgia Bariátrica , Obesidade Mórbida/complicações , Obesidade Mórbida/cirurgia , Apneia Obstrutiva do Sono/etiologia , Cirurgia Bariátrica/métodos , Desvio Biliopancreático/métodos , Feminino , Derivação Gástrica/métodos , Gastroplastia/métodos , Humanos , Laparoscopia , Masculino , Obesidade Mórbida/fisiopatologia , Apneia Obstrutiva do Sono/fisiopatologia , Resultado do Tratamento , Redução de Peso
4.
Obes Surg ; 22(5): 832-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22350987

RESUMO

Laparoscopic sleeve gastrectomy (LSG) is a relatively new bariatric surgical procedure associated with an acceptable weight loss and a relatively low morbidity. There is existing evidence suggesting bariatric surgery resolves or improves hypertension. The purpose of this study is to systematically review the effect of LSG on hypertension. An electronic search method was primarily used for identification of the studies. We performed a comprehensive search of all electronic databases (MEDLINE, PubMed, Embase, Scopus, Dare, Clinical Evidence, BIOSIS, Previews, TRIP, Web of Science, Health Technology Database, Conference abstracts, clinical trials, and the Cochrane Library database) using broad search terms. All human studies from August 2000 to September 2011 were included. After an initial screening, a total of 326 studies were identified. After assessment of these studies based on our exclusion criteria, 222 studies were considered for the abstract review. A total of 33 studies were identified after a careful screening, involving a total of 3,997 patients. The mean pre-operative body mass index (BMI) was 49.1 ± 7.5 kg/m(2) (range 37-68). The average follow-up time was 16.9 ± 9.8 months (range 12-48). The mean post-operative BMI was 36 ± 7.0 kg/m(2) (range 25.6-54). LSG resulted in resolution of hypertension in 58% of patients. On average, 75% of patients experienced resolution or improvement of their hypertension. Based on our systematic review, LSG has a significant effect on hypertension, inducing resolution or improvement in the majority of cases. Therefore, LSG remains a viable surgical option in obese patients with hypertension.


Assuntos
Pressão Sanguínea , Gastroplastia/métodos , Hipertensão/prevenção & controle , Laparoscopia , Obesidade Mórbida/cirurgia , Redução de Peso , Índice de Massa Corporal , Feminino , Seguimentos , Humanos , Hipertensão/etiologia , Hipertensão/fisiopatologia , Laparoscopia/métodos , Masculino , Obesidade Mórbida/complicações , Obesidade Mórbida/fisiopatologia , Resultado do Tratamento
5.
J Surg Oncol ; 99(7): 428-32, 2009 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-19347885

RESUMO

BACKGROUND AND OBJECTIVES: The role of surgical management in duodenal lymphoma is controversial due to the rarity of this tumor subtype. A retrospective review of a provincial cancer registry was performed to assess the rationale for surgical management in duodenal lymphoma. METHODS: Patient demographics, presentations, pathologies, surgical interventions, treatment, and associated disease-specific survival were assessed and descriptively presented. RESULTS: From 1985 to 2005, 23 patients (mean age 58 years [22-82]) were diagnosed. The most common histology was large B-cell lymphoma (74%). A significant proportion presented in a complicated fashion: obstruction (30%), perforation (17%), and hemorrhage (4%). Eight patients (35%) were treated with surgery alone, eight (35%) with surgery and chemotherapy, five (22%) with chemotherapy alone, and two (9%) with supportive care. Of those treated with surgery, indications were mostly emergent conditions including obstruction (58%), perforation (33%), and hemorrhage (8%). Overall median follow-up was 14 months (1-168 months) and overall median survival was 12 months (1-168 months). There were no significant differences in survival by histology, stage, or treatment type. CONCLUSIONS: Chemotherapy continues to represent the therapeutic mainstay for GI lymphomas. However, in duodenal lymphoma, a high proportion of patients require surgery mainly because of complicated presentations.


Assuntos
Neoplasias Duodenais/cirurgia , Linfoma de Células B/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/uso terapêutico , Neoplasias Duodenais/tratamento farmacológico , Feminino , Seguimentos , Humanos , Linfoma de Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Estudos Retrospectivos , Análise de Sobrevida
6.
J Cell Physiol ; 201(1): 146-54, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15281097

RESUMO

Indoleamine 2,3-dioxygenase (IDO) is an intracellular tryptophan-catabolizing enzyme possessing various immunosuppressive properties. Here, we report the use of this enzyme to suppress the proliferation of peripheral blood mononuclear cells (PBMC) co-cultured with IDO-expressing fibroblasts of an allogeneic skin substitute in vitro. Fetal foreskin fibroblasts populated within collagen gel (FPCG) were treated with interferon-gamma (IFN-gamma) conjugated with a temperature-sensitive polymer to induce the expression of IDO mRNA and protein. SDS-PAGE showed successful conjugation of IFN-gamma with the temperature-sensitive polymer. Expression of IDO mRNA was evaluated by Northern analysis. IDO enzyme activity was evaluated by the measurement of kynurenine levels. The results of Northern blot analysis showed an induction of IDO mRNA expression when treated with polymer-conjugated IFN-gamma. Kynurenine levels, as a measure of IDO bioactivity, were significantly higher in IFN-gamma-treated fibroblasts than in controls (P < 0.001). In a lasting effect experiment, the expression of IDO mRNA in FPCG treated with polymer-conjugated IFN-gamma was significantly longer than in those treated with free (non-conjugated) IFN-gamma (P < 0.001). IFN-gamma radiolabeling showed a prolonged retention of IFN-gamma within collagen gel in its polymer-conjugated form, compared to its free form. Presence of IDO protein in FPCG was demonstrated by Western analysis even 16 days after removal of the conditioned medium (containing released IFN-gamma). To demonstrate the immunosuppressive effects of IDO on the proliferation of PBMC, IDO-expressing FPCG treated with polymer-conjugated IFN-gamma were co-cultured with PBMC for a period of 5 days. The results showed a significant reduction in proliferation of PBMC co-cultured with IFN-gamma-treated IDO-expressing fibroblasts, compared to those co-cultured with non-IDO-expressing fibroblasts (P < 0.001). The addition of an IDO inhibitor (1-methyl-D-tryptophan) reversed the suppressive effects of IDO on PBMC proliferation. In conclusion, IDO expression in FPCG suppresses the proliferation of immune cells in vitro. The use of a temperature-sensitive polymer further prolongs the effect of IFN-gamma on the expression of IDO. Therefore, modulating IDO levels in situ might be an alternative for prolonging the survival of skin allografts.


Assuntos
Antineoplásicos/farmacologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/fisiologia , Interferon gama/farmacologia , Triptofano Oxigenase/genética , Antineoplásicos/química , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Técnicas de Cocultura , Colágeno , Fibroblastos/citologia , Géis , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Humanos , Indolamina-Pirrol 2,3,-Dioxigenase , Interferon gama/química , Cinurenina/metabolismo , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/efeitos dos fármacos , Polímeros/química , Polímeros/farmacologia , RNA Mensageiro/metabolismo , Temperatura , Triptofano/metabolismo , Triptofano Oxigenase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA